Clinical Trial Update: KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial updating the efficacy of KRT-232 versus best available therapy for relapsed/refractory myelofibrosis (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• KRT-232

Snippet

Sponsor: Kartos Therapeutics, Inc. | Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF) | Phase 2, Phase 3 | Status: UNKNOWN